KURA - Kura Oncology - Stock Price & Catalysts • BiopharmIQ

BiopharmIQ

Try Pro Free Already have an account? Login

Enterprise Value

502.1M

Cash

405.9M

Avg Qtr Burn

-28.44M

Short % of Float

9.11%

Insider Ownership

1.94%

Institutional Own.

-

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ziftomenib) (menin inhibitor) (KO-539) Details Acute myeloid leukemia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tipifarnib Details T cell lymphoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tipifarnib Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KO-2806 (FTI inhibitor) Details Solid tumor/s	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.